Aperio Group’s Whitehawk Therapeutics WHWK Stock Holding History

Aperio Group’s Portfolio WHWK Stock Details WHWK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-35	Closed	–	–	2790
2019 Q2	$0	Buy	+35	New	+$531	﹤0.01%	3045

Other funds holding WHWK

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JIC

Johnson Investment Counsel Cincinnati, Ohio $12.4B AUM 17.21% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

NRS

Neville Rodie & Shaw New York $1.55B AUM 46.95% 1-Year Est. Return

Aperio Group's WHWK Position: Q3 2019 in Review

Aperio Group sold out of Whitehawk Therapeutics (WHWK) in Q3 2019, closing a stake of 35 shares.

Aperio Group first reported a position in WHWK in Q2 2019 and held it in 1 quarter. The position peaked at $0 in Q2 2019. 24 funds tracked by Wall St. Rank hold WHWK as of Q3 2019.

Aperio Group reported no remaining Whitehawk Therapeutics position as of Q3 2019 after selling out during the quarter.
Aperio Group sold 35 Whitehawk Therapeutics shares in Q3 2019.
Aperio Group first reported a position in Whitehawk Therapeutics in Q2 2019 and held it in 1 quarter.
Aperio Group's Whitehawk Therapeutics position peaked at $0 in Q2 2019.
24 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q3 2019.

Based on Aperio Group's 13F filing for Q3 2019, filed 6 Nov 2019.